Apricus Biosciences announced that the company has filed its response to questions received from Swissmedic, the Agency for Therapeutic Products in Switzerland, relating to its marketing application ...

SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that its ...

Apricus Biosciences, Inc. has received the Belgium's Ministry of Social Affairs, Public Health and Environment national phase approval to Vitaros, indicated for the treatment of patients with erectile ...

announced today its filing of a marketing application for Vitaros as a treatment for patients with erectile dysfunction in Switzerland, with Swissmedic, the Swiss Agency for Therapeutic Products. "We ...

SAN DIEGO, April 28, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it has filed a marketing application in Europe for Vitaros ® as a treatment ...

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company advancing innovative medicines in urology ...

There has been much buzz lately about the side effects of Apricus Bio’s (APRI) topically applied erectile dysfunction treatment, Vitaros. Vitaros is an alprostadil-based cream and stands as a ...

SAN DIEGO, May 19, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it will file a marketing application in Switzerland for Vitaros ® as a ...

The Company has one approved product, Vitaros (R), for the treatment of erectile dysfunction, which is now approved in Europe and Canada and will be commercialized by Apricus Bio's marketing partners ...